Organon & Co. (OGN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US68622V1061
Organon & Co. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 6.22 bn USD |
| Gross profit | 3.31 bn USD |
| EBIT | 929.00 m USD |
| Net income | 187.00 m USD |
| Diluted EPS – continuing operations | 0.72 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
More stocks
- MARUWA Co Ltd (5344.T)
- Canadian Apartment Properties Real Estate Investment Trust (CAR.UN.TO)
- Xinfengming Group Co Ltd (603225.SS)
- Hoegh Autoliners ASA (HAUTO.OL)
- Bluestar Adisseo Co (600299.SS)
- Ocado Group PLC (OCDO.L)
- Ta Chen Stainless Pipe Co Ltd (2027.TW)
- Vidrala SA (VID.MC)
- Manchester United Ltd (MANU)
- Beijing Tiantan Biological Products Corp Ltd (600161.SS)
- Zhengzhou Coal Mining Machinery Group Co Ltd (601717.SS)
- China Resources Pharmaceutical Group Ltd (3320.HK)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.